iShares Russell 2000 ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares Russell 2000 ETF trades at $278.31 (market cap $77.70B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: iShares Russell 2000 ETF is far larger — about 3.1× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| IWM | RPRX | |
|---|---|---|
Market Cap | $77.70B | $25.27B |
Volume | 35,598,983 | 3,671,183 |
52-Week High | $305.06 | $63.96 |
52-Week Low | $229.13 | $35.44 |
Typical Hold Time | 83 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
IWM trades at $277.72, down 1.27% amid broader small-cap weakness. Technical indicators show a bearish trend with resistance at $278 and support at $275. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices over the past decade. Recent news highlights concerns about small-cap risk premiums and competition from more selective small-cap funds.
The outlook remains cautious as rising interest rates pressure small-cap valuations. Opportunities exist for long-term investors seeking diversification from tech-heavy large caps, but near-term risks include economic sensitivity and narrow market breadth. The bearish technical setup suggests further downside potential unless macroeconomic conditions improve.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →